Baseline CD3+CD56+ (NKT-like) Cells and the Outcome of Influenza Vaccination in Children Undergoing Chemotherapy

Evelin A. Leibinger1*, Gábor Pauler2, Noémi Benedek1, Timea Berki3, István Jankovics4, Richard McNally5 and Gábor Ottóffy1*

1 Division of Pediatric Hematology and Oncology, Department of Pediatrics, University of Pécs Medical School, Pécs, Hungary, 2 Institute of Mathematics and Informatics, University of Pécs, Pécs, Hungary, 3 Department of Immunology and Biotechnology, University of Pécs Medical School, Pécs, Hungary, 4 Department of Virology, National Center for Epidemiology, Budapest, Hungary, 5 Population Health Sciences Institute, Newcastle University, Newcastle, United Kingdom

Background: In children undergoing chemotherapy yearly influenza vaccination is recommended by treatment protocols. We investigated the relationship between cellular immunity and the antibody response to inactivated influenza vaccines.

Methods: 25 patients (age: 2-18 years) undergoing chemotherapy for different malignancies participated in our study. Flow cytometric detection of peripheral blood lymphocyte subpopulations together with hemagglutination inhibition antibody titers were measured before and 21-28 days after vaccination. We examined the ratio and total numbers of CD3+, CD4+, CD8+ T cells, activated helper (CD3+CD4+CD25low), regulatory (CD3+CD4+CD25high), naive (CD3+CD45RA+) and memory (CD3+CD45RO+) T cells, CD56+NK, and CD3+CD56+ (NKT-like) cells. Relationships between specific antibody responses (seroprotection, seroconversion, geometric mean titer (GMT), geometric mean fold increase (GMFI)) and the ratios and counts of lymphocyte subpopulations were evaluated using one-way ANOVA and the paired sample t test after dichotomization according to age-related reference values.

Results: Patients with CD4+ lymphocyte levels in the normal age-specific range showed significantly better response regarding postvaccination GMT elevation for H1N1 and H3N2 strains (97.52 vs. 19.2, p=0.019, 80 vs. 14.43, p=0.021, respectively). GMFI results were significant only against B strain (2.69-fold vs. 1.23-fold, p=0.046). Prevaccination CD3+CD56+ (NKT-like) cells above predicted values according to age showed significant associations both in postvaccination GMT elevation (H1N1: 75.11 vs. 14.14, p=0.010; H3N2: 62.18 vs. 11.22, p=0.012; B: 22.69 vs. 6.67, p=0.043) and GMFI against all three strains (H1N1: 3.76-fold vs. 1.06-fold, p=0.015; H3N2: 2.74-fold vs. 1, p=0.013; B: 2.57-fold vs. 1, p=0.008). By one-way ANOVA, we found a positive relation between absolute lymphocyte cell count above 1000/µl and the postvaccination GMT elevation against H3N2 (12.81 vs. 56.56, p=0.032), and GMFI regarding H1N1 (12.22-fold vs. 3.48-fold, p=0.044).
INTRODUCTION

Chemotherapy induced cytopenias cause prolonged immunosuppression in patients with malignancies resulting in increased susceptibility for pathogens. An annually recurring potential risk is infection with influenza. It can cause severe illness and complications as well as delays in treatment regimens thus threatening the outcome of cancer treatment (1, 2). The recommended vaccination offers the possibility to prevent infection and its complications (3).

Furthermore, investigating the immune response and factors that might be associated with successful immunization of such an immunocompromised population gives us a unique opportunity to evaluate the underlying immunological mechanisms and find targets for vaccine improvement.

In a previous study we evaluated the immune response and safety of concomitant trivalent-inactivated vaccine for seasonal influenza viruses (H1N1, H3N2 and B), and monovalent-inactivated vaccine for the 2009 pandemic influenza A virus in children undergoing chemotherapy (4). In agreement with several other studies (5–9), we verified that a higher baseline absolute lymphocyte count may enhance the immune response to influenza vaccination. A remaining question is which specific lymphocyte subpopulation could be responsible for this enhancement.

In recent years cellular, especially T cell responses gained increasing importance in influenza vaccine research and development (10–12). One such area of ongoing research are natural killer (NK) T cells, also called as NKT-like cells, a heterogeneous group of T lymphocytes that confer natural immunity. These cells have the phenotypic characteristics of both T cells and NK cells and function as a link between innate and adaptive immunity. NKT-like cells include a wide group of innate T lymphocyte populations, such as γδT cells, and CD1d- and MR-1-restricted T cells which have an important immunoregulatory function. Unlike the major histocompatibility complex (MHC)-restricted T cells, these cells possess a restricted repertoire of T cell receptors, perform rapid effector responses and recognize a limited selection of non-peptide molecules, presented by the MHC class I-like molecule CD1d. Upon activation, NKT cells rapidly release large quantities of multiple cytokines and chemokines capable of boosting adaptive immune responses. They are capable of stimulating a wide array of immune cells that enhance vaccine-mediated immune responses (13).

Induction of NKT cells with a special adjuvant has resulted in improved immune responses in several animal models (14) of influenza vaccination. NKT cells show similarity in mammals so induction of these cells during vaccination might be promising in humans as well. Furthermore, based on animal investigations, some authors suggest that NKT cell induction might have a role also in the treatment of influenza infection (15).

Every finding in humans that correlates with results of animal investigations supports a similar role of NKT cells in humans and leads us closer to improved prevention or treatment of influenza virus infection.

In our study we investigated the relationship between cellular immunity and the response to influenza vaccines in children receiving chemotherapy with different types of malignancies.

Conclusions: In addition to verifying the predictive value of absolute lymphocyte count above 1000/µl, our results suggest an association between NKT-like cell counts and the specific antibody response against all three investigated influenza strains in highly immunosuppressed patients. Furthermore, prevaccination CD4+ lymphocyte levels in the normal age-specific range may influence seroresponse.

Keywords: influenza vaccines, pediatrics, immunosuppression, natural killer T-cells, lymphocyte subsets, cellular immunity, CD4+ T-cells

MATERIALS AND METHODS

Patient Characteristics

Twenty-five consecutively treated patients (11 males and 14 females) were enrolled in our study during the influenza season periods of 2016/2017 and 2017/2018. Median age was 6 years (range 2 to 18 years). The underlying diseases were hematologic malignancies in the majority of participants (19 patients), while the remaining 6 cases had various solid tumors. All patients had been receiving chemotherapy at the Division of Pediatric Hematology and Oncology of the University of Pécs within 1 month before vaccination, and all continued to receive scheduled chemotherapy afterwards. Nine patients were undergoing maintenance therapy and sixteen children were receiving intensive cytostatic treatment (Table 1).

Exclusion criteria were the following: recent history of influenza vaccination, confirmed influenza infection prior to vaccination, history of egg allergy, administration of other vaccines during the study period. One patient was eventually excluded from the study due to lack of adherence to follow-up visits.

Study Design, Vaccine and Schedule

The protocol for vaccination was designed in accordance with the recommendations of the Infectology Department of the Hungarian National Healthcare Advisory Board, based on data...
received from the Hungarian National Center of Epidemiology (16, 17).

The Institutional Review Board of the University of Pécs authorized the protocol for this study (3672.316-2954/2010). Sample collections were performed concurrently with the routine blood sampling involved in cancer treatment. Written consent was obtained from the parents of each child.

In both seasons, a whole-virus, trivalent, inactivated, adjuvanted influenza vaccine (3Flua rt - Fluart Innovative Vaccines Ltd., Budapest, Hungary) was in use for vaccination. Each preparation contained aluminium phosphate gel adjuvant and 6 µg haemagglutinin of each strain per 0.5 ml. Strains were selected according to the recommendations of the World Health Organization for the northern hemisphere for influenza vaccine composition for respective seasons: A/Hong Kong/4801/2014 (H3N2)-like, B/Brisbane/60/2008-like, A/California/7/2009 (H1N1)pdm09-like (A/California/7/2009, NYMC X-181) in 2016/2017 and A/Michigan/45/2015 (H1N1)pdm09-like in 2017/2018.

Fifteen patients were younger than 10 years old, and therefore received 0.25 ml of the vaccine, while ten participants received 0.5 ml of the vaccine.

In patients receiving maintenance treatment, vaccine was given without discontinuation of therapy. During intensive treatment, vaccination was scheduled in all patients 2-3 days before the next cytostatic treatment according to the recommendations of the Hungarian National Healthcare Advisory Board.

### Sample Collection and Serological Analysis

Blood samples were taken from each participant before vaccination and 28 days afterwards, mostly via central venous catheter for measurements of hemagglutination inhibition (HI) titer, immunoglobulin level, white blood cell count and flow cytometric analysis.

Three millilitres of serum were separated by centrifugation, then immediately frozen and stored at -80°C until the laboratory measurements on HI antibody titers were performed. Titers against the virus strains were measured by hemagglutination inhibition with chicken red blood cells following recommended procedures (18). All serologic tests were done at a single central laboratory (Department of Virology, National Center of Epidemiology, Budapest, Hungary). Each pair of sera were tested in complete duplicate series on the same day with the use of identical reagents.

The geometric mean HI antibody titer (GMT), seroprotection (defined as a titer level of ≥1:40) rate, seroconversion (defined a ≥4-fold increase in titer from baseline or a postvaccination titer level of ≥1:40 if the baseline titer was undetectable) rate, and GMT fold increase (GMFI: GMT ratio of postvaccination titer to prevaccination titer) were calculated.

### Multiparametric Flow Cytometry Analysis of Phenotypes

The following anti-human monoclonal antibodies were used: anti-CD3-FITC, anti-CD8-PE, anti-CD4-PerCP, anti-CD56-
PECy5, anti-CD25-PE, anti-CD45RA-PE and anti-CD45RO-PerCP (all from BD Biosciences). The 50 µl blood sample (EDTA) was incubated with the appropriate antibody cocktails for 30 minutes on ice, washed twice in phosphate buffered saline and fixed with 1% paraformaldehyde prior flow cytometric analysis using a FACSCalibur cytometer with CellQuestPro software. At least 10,000 cells were collected in the lymphocyte gate and analyzed. CD3+, CD4+, CD5+, CD8+ T cells, CD3+ CD4+CD25- “resting T\textsubscript{helper} cells”, CD3+CD4+CD25\textsuperscript{low} “activated” and, CD3+CD4+CD25\textsuperscript{high} “regulatory” T cells were detected and their absolute cell numbers were calculated. We followed naive CD3+CD45RA+ and CD3+CD45RO+ memory T cell percentages and absolute cell counts, CD3+CD56+ NKT-like and CD56+ NK cell ratio and absolute cell counts. CD3/CD45 positive cells were further analyzed for their CD4, CD8 and CD25 expression. Naive and memory T cells were detected with simultaneous CD3/CD45RA/CD45RO staining, NK cells and NKT cells were analyzed from the lymphocyte gate based on their CD3/CD56 positivity. For each of the gated cell populations the percentages of cells were analyzed. Gating strategies are presented in Figure 1.

**Adverse Reactions and Medical Conditions**

Baseline assessments on day 0 consisted of gathering demographic data, medical history and physical examination. We examined each patient on a weekly basis by physical and laboratory (complete blood count) examination during the follow-up period, until the final blood sampling was obtained for serologic study. Possible vaccine-related adverse events were monitored closely. On follow-up visits, standard medical history and medications administered since the last visit were summarized, and physical examination was performed prior to blood sample collection. Safety variables were recorded during follow-up visits for patient history and physical examination.

**Statistical Analysis**

Data were analyzed using one-way ANOVA and paired sample t test using the package SPSS 20.0. F-tests for main effects were obtained using one-way ANOVA (weighted method). For one-way ANOVA analyses we divided our sample of patients into two groups based on age-related reference values and where these were not available, statistically determined cut-off values for each cellular parameter to investigate whether a certain cell count or ratio might be related to better serologic response.

We handled pre- and postvaccination HI titers in two ways. We analyzed GMT levels at pre- and postvaccination: due to skewed distributions, analyses were performed on the natural log of HI titer and arithmetic means were converted to GMT with exponential transformation.

We calculated values of GMFI between pre- and postvaccination: as it was discussed earlier (19) that in a population which is not entirely seronegative before immunization, prevaccination HI titer levels have significant influence on postvaccination titers, we examined the ratio of post-/prevaccination GMFs.

Due to the methodology of serologic analyses, negative specimens (undetectable titer levels) were assigned a nominal value of 5 for the purposes of statistical analysis. For each test, a p-value < 0.05 was considered significant.

---

**FIGURE 1** | Gating strategies. At least 10,000 cells were collected in the lymphocyte gate and analyzed. CD3+, CD4+, CD5+, CD8+ T cells, CD3+CD4+CD25- “resting T\textsubscript{helper} cells”, CD3+CD4+CD25\textsuperscript{low} “activated” and, CD3+CD4+CD25\textsuperscript{high} “regulatory” T cells were detected and their absolute cell numbers were calculated. We followed naive CD3+CD45RA+ and CD3+CD45RO+ memory T cell percentages and absolute cell counts, CD3+CD56+ NKT-like and CD56+ NK cell ratio and absolute cell counts. CD3/CD45 positive cells were further analyzed for their CD4, CD8 and CD25 expression. Naive and memory T cells were detected with simultaneous CD3/CD45RA/CD45RO staining, NK cells and NKT cells were analyzed from the lymphocyte gate based on their CD3/CD56 positivity. For each of the gated cell populations the percentages of cells were analyzed.
We analyzed day 0 results for the following parameters: absolute lymphocyte count, total CD3+ T, CD4+ T, and CD8+ T, cell count, CD4/CD8 ratio, CD3+CD45RA+ naive and CD3+CD45RO+ memory T cell count and naive/memory T cell ratio. Furthermore, we followed Treg cell (CD3+CD4+CD25High) and activated T_h (CD3+CD4+CD25Low) cell counts, CD3+CD4+ CD25High/Low ratio, CD3+CD56+ NKT-like and CD56+ NK cell counts; and compared them with postvaccination HI titers (postvaccination GMT) or with the GMFI between day 0 and day 28. We conducted these studies (postvaccination GMT and GMFI) separately for each virus strain: H1N1pdm09-like, H3N2-like and B/Brisbane strain.

RESULTS

Antibody Responses

GMTs, seroprotection and seroconversion rates were calculated on day 0 and on day 28. GMTs of antibodies to different influenza virus strains are listed in Table 2. All postvaccination GMTs were higher than prevaccination GMTs, regarding H1N1, H3N2 and B/ Brisbane strains, and examining GMFI, increases between them were significant. Seroprotection and seroconversion rates according to virus strains are shown in Table 3.

Flow Cytometry Results According to Age-Related Reference Values

According to the age-matched reference intervals provided by Huenecke et al. (20) we observed that in most cases, total lymphocyte count, CD3+, CD4+, CD8+ and CD56+ counts were under the lower limit of age-related intervals. CD4/CD8 ratio was within the normal range in 52% of our patients. Interestingly, percentages of CD3CD25+ activated T cells and CD4CD25+ activated T cells were in normal ranges in all of our patients. For certain subpopulations however, no age-dependent reference ranges were available. Since intervals were not available for CD3+CD56+ NKT cells, we used the predicted values and found that 50% of our patients had results under this cut-off value. Descriptive results are summarized in Table 4.

Relationship of Lymphocyte Subpopulations and the Immune Response

Supplementary Table 1. shows the absolute cell numbers and percentages analyzed using flow cytometry and the ratios of certain cells. By assessing specific cell population counts, we examined the relations between lymphocyte subpopulations and their ratios and the outcome of vaccination. The associations of prevaccination T cells and GMT and GMFI by different strains is shown in Tables 5 and 6. As mentioned before, a p-value < 0.05 was considered significant for each test.

By one-way ANOVA, we did not find a relation between age-related baseline absolute lymphocyte counts and postvaccination GMT and GMFI against the three influenza strains. However, after comparing the immune response of patients with absolute lymphocyte cell counts below or above 1000/µl, these results suggested a positive association between higher cell counts and vaccine response. We found a positive relation with the postvaccination GMT elevation against H3N2 (12.81 vs. 56.56), and GMFI regarding H1N1 (1.22-fold vs. 3.48-fold).

Regarding CD4+ lymphocytes, we expected better immune responses in patients with CD4+ cell counts in the normal age-specific range and they showed significantly better results in postvaccination GMT elevation for H1N1 and H3N2 strains (97.52 vs. 19.2 and 80 vs. 14.43, respectively). However, GMFI results were significant only against B strain.

Analyses of age-related predicted values of CD3+CD56+ cells showed significant relations both with postvaccination GMT elevation and GMFI against all three strains. Patients with CD3+CD56+ counts above the predicted threshold had better responses in GMT after vaccination (H1N1: 75.11 vs. 14.14; H3N2: 62.18 vs. 11.22; B: 22.69 vs. 6.67). GMFI results were

| TABLE 2 | GMT and GMFI values on day 0 (prevaccination) and day 21-28 (postvaccination) according to virus strains. |
|---------------------|---------------------|---------------------|---------------------|
|                      | H1N1                | H3N2                | B                   |
| Prevaccination GMT [95% CIs] | 16.93 [9.59, 29.88] | 15.58 [9.01, 26.93] | 7.79 [5.20, 11.68] |
| Postvaccination GMT [95% CIs] | 30.84 [15.73, 60.45] | 23.78 [11.59, 48.77] | 11.55 [6.27, 21.26] |
| GMFI [95% CIs] | 1.88 [1.10, 3.23] | 1.58 [1.04, 2.41] | 1.54 [1.06, 2.24] |
| p values of GMFI | 0.023 | 0.032 | 0.025 |

GMT, Geometric Mean Titer; GMFI, Geometric Mean Fold Increase.

95% CIs are expressed as lower/upper bounds of GMT or GMFI values.

| TABLE 3 | Pre- and postvaccination rates for seroprotection† and seroconversion‡ by virus strains. |
|---------------------|---------------------|---------------------|---------------------|
|                      | H1N1                | H3N2                | B                   |
| Prevaccination seroprotection | 11/24 (46) | 9/24 (38) | 3/24 (13) |
| Postvaccination seroprotection | 12/24 (50) | 10/24 (42) | 5/24 (21) |
| Seroconversion | 6/24 (25) | 4/24 (17) | 3/24 (13) |

†Seroprotection defined as a HI titer ≥40.
‡Seroconversion defined as at least four-fold rise in titer postvaccination.
Analyses of CD4/CD8 ratio, CD3+CD45RA+ naive and CD3+CD45RO+ memory T cell counts, naive/memory T cell ratio, CD3+, CD8+, and CD56+ NK cell counts did not show significant associations with immune response against any of the strains.

**Adverse Reactions**

We recorded no local adverse reactions (injection site induration, erythema, swelling or warmth). No medical intervention was necessary. No vaccine related serious adverse event was observed. There were no breakthrough in influenza infections.

**DISCUSSION**

Myelosuppressive effects of therapeutic protocols are considerably diverse depending on the underlying malignancy and the cytotoxic agents administered. In hematological malignancies immunosuppressive effects persist during...
The most noteworthy result we recognised was the positive association of day 0 CD3+CD56+ (NKT-like) cell count above the age-specific predicted values and both postvaccination GMT and GMFI. We observed the most predictive role of these cells for the seroresponse against all strains of influenza virus.

According to Romero-Olmedo et al. (32), human peripheral blood CD3+CD56+ cells constitute a phenotypical continuum of different natural T cell subsets such as CD8+ or CD4-CD8- (double negative), γδ+ and MAIT cells. They demonstrated that both in healthy and allergic adults, CD3+CD56+ cells were actually part of all major T cell groups rather than a separate group.

treatment and recovery can take more than 12 months after cessation of therapy. Acute lymphocytic leukemia patients have decreased lymphocyte counts in all major groups compromising both humoral and cellular immunity possibly affecting preexisting humoral protection resulting from childhood vaccinations or previous infections. Total leukocyte and lymphocyte counts were found to be comparable to healthy

### TABLE 6 | Relations between different prevaccination cellular parameters and GMFI by virus strains. Significant results are written in bold.

| Group† | n  | H1N1 |  | H3N2 |  | B |  |
|-------|----|------|---|------|---|---|---|
| Lymphocyte count, n/μl | <1000 | 14 | 1.22 [0.69, 2.17] | 0.044 | 1.56 [0.78, 3.13] | 0.926 | 1.16 [0.92, 1.46] | 0.061 |
| | ≥1000 | 10 | 3.48 [1.26, 9.59] | 1.62 [1.01, 2.63] | 1.26 [0.47, 3.4] | 1.64 [1.07, 2.51] | 0.902 | 2.30 [0.96, 5.47] | 0.377 |
| Lymphocyte count, n/μl | <Norm | 21 | 1.87 [1.01, 3.46] | 0.935 | 1.64 [1.02, 2.65] | 0.677 | 1.64 [1.07, 2.51] | 0.902 | 1.14 [1.01, 2.35] | 0.377 |
| | ≥Norm | 3 | 2 [0.36, 11.19] | 1.26 [0.47, 3.4] | 1.64 [1.07, 2.51] | 0.887 | 1.59 [0.99, 2.55] | 0.294 |
| CD3+ absolute count, n/μl | <Norm | 20 | 1.57 [0.93, 2.64] | 0.114 | 1.57 [0.95, 2.58] | 0.902 | 1.41 [1.04, 1.92] | 0.902 | 1.23 [0.96, 1.57] | 0.902 |
| | ≥Norm | 4 | 4.76 [0.26, 86.51] | 1.68 [0.59, 4.83] | 1.68 [0.59, 4.83] | 1.28 [0.15, 37.48] | 2.38 [0.15, 37.48] | 2.38 [0.15, 37.48] | 0.046 |
| CD4+ absolute count, n/μl | <Norm | 17 | 1.39 [0.79, 2.44] | 0.062 | 1.44 [0.81, 2.58] | 0.477 | 1.23 [0.96, 1.57] | 0.887 | 2.69 [0.75, 9.63] | 0.046 |
| | ≥Norm | 7 | 4 [1.05, 15.19] | 2 [1.18, 3.38] | 2 [1.18, 3.38] | 2 [1.18, 3.38] | 2 [1.18, 3.38] | 2 [1.18, 3.38] | 0.008 |
| CD4/CD8 ratio | <Norm | 12 | 2.38 [1.02, 5.52] | 0.386 | 1.78 [0.96, 3.31] | 0.561 | 1.5 [0.77, 2.91] | 0.887 | 1.50 [0.77, 2.91] | 0.887 |
| | ≥Norm | 12 | 1.5 [0.68, 3.28] | 1.41 [0.73, 2.75] | 1.41 [0.73, 2.75] | 1.59 [0.99, 2.55] | 1.59 [0.99, 2.55] | 1.59 [0.99, 2.55] | 0.008 |
| CD3+CD56+ (NKT-like) absolute count, n/μl | <Pred | 12 | 1.06 [0.59, 1.89] | 0.015 | 1 [0.51, 1.97] | 0.013 | 1 [1, 1] | 0.008 | 1 [1, 1] | 0.008 |
| | ≥Pred | 11 | 3.76 [1.6, 9.41] | 2.74 [1.77, 4.23] | 2.74 [1.77, 4.23] | 2.74 [1.77, 4.23] | 2.74 [1.77, 4.23] | 2.74 [1.77, 4.23] | 0.008 |

†Grouping strategies: ‘Norm’ refers to the lower limit of age-related reference intervals, whereas ‘Pred’ refers to the age-specific predicted values of CD3+CD56+ cells. GMT, Geometric Mean Titer; GMFI, Geometric Mean Fold Increase, n, number of patients.
Expression of CD56 has been associated with cytotoxic and immunostimulatory properties (33) and has been found on several activated cell types that also show cytotoxic properties. This finding suggests that CD56 is more of a sign of activation than a characteristic phenotypical marker.

However, we think that these results might have more importance in influenza vaccine research. CD3 and CD56 markers have been associated with NKT cells as well. Although the terminology of these cells is quite discordant (34), they are often referred to as NKT-like cells, a heterogeneous group of T cells that have been the target of extensive research regarding influenza vaccines. CD3+CD56+ (NKT-like) cells can carry out MHC-unrestricted cytotoxicity and secrete many kinds of cytokines. They confer natural immunity and play a part in helping the differentiation of helper T cells.

Several research groups have demonstrated that activation of NKT cells contribute to the humoral immune response to different microbes (35), however, most of these studies were conducted in animals. In connection with influenza vaccination, these studies demonstrated that use of glycolipid adjuvants (e.g. α-galactosylceramide) as NKT cell activators lead to better immunological response (36–38). Regarding recent investigations into the immunology of SARS-CoV-2 infection, lower percentages of CD3+CD56+ (NKT-like) cells have been observed in COVID-19 subjects when compared to healthy controls. Further comparison of patients with severe and non-severe pneumonia showed significantly lower percentages in the former group of subjects (39).

A possible theory is that the relationship between the immune response and the number of NKT-like cells in this immunosuppressed population might originate from their homing characteristics. Most of these cells migrate and reside to different tissues (40), therefore they might form a pool of mobile cells during chemotherapy. However there are only a few reports about findings that support this phenomenon (41, 42).

We would like to further investigate and confirm our results by an extended, nationwide study of the connection between prevaccination lymphocyte subpopulations, especially NKT-like cells (with more detailed identification) and the outcome of influenza vaccination in children undergoing chemotherapy.

As we expected, a modest immunogenicity was observed in our patients. These findings seemed to be in agreement with published reports.

Our study has several limitations. The patient sample was considerably heterogeneous in respect of specific hemato-oncologic diseases and types of cytostatic treatment. Statistically the sample size was quite small and no control group was established. Consequently, our results should be treated with caution. Nevertheless, we tried to compensate it with sampling mostly those patients, who received parenteral cytostatic treatment. Additionally, we used a conventional p value of 0.05.

CONCLUSION

To our knowledge, we revealed for the first time some possible connections between T-lymphocyte subpopulation counts at the time of vaccination and seroresponse to influenza vaccination in immunosuppressed patients. From a practical point of view, although in a small, but highly immunosuppressed study population our investigation suggests a possible positive association between NKT-like cells and postvaccination GMT and GMFI in all three strains following influenza vaccination.

After verifying our results on a larger sample with a control group, it can outline a promising direction for research to further specify the associations of the previously mentioned cell populations and their ratios and serologic immunity. Our investigation highlights the need for age-specific reference ranges for T cell subpopulations. Moreover, should our results be verified, they could support the possible advantages of incorporating NKT cell-activating adjuvants into influenza vaccines.

DATA AVAILABILITY STATEMENT

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

ETHICS STATEMENT

The studies involving human participants were reviewed and approved by Institutional Review Board of the University of Pécs, Pécs, Hungary (3672.316–2954/2010). Written informed consent to participate in this study was provided by the participants’ legal guardian/next of kin.

AUTHOR CONTRIBUTIONS

EL: Data curation (supporting); Writing – Original Draft Preparation (equal); Writing – Review and Editing (equal). GP: Data curation (lead); Formal analysis (lead); Investigation (equal); Visualization; Writing – Review and Editing (equal). NB: Conceptualization (equal); Data curation (equal); Investigation (equal). GO: Conceptualization (equal); Data curation (equal); Investigation (equal); Funding acquisition; Investigation (equal); Project administration (lead); Writing – Original Draft Preparation (equal); Writing – Review and Editing (equal). All authors contributed to the article and approved the submitted version.

FUNDING

Statistical work was partially financed by 2020-4.1.1-TKP2020, the Subprogram 3: “Innovation for sustainable life and environment” of “Scientific Field Excellence Program 2020” of the Hungarian Government.

Leibinger et al. NKT-Like Cells and Influenza Seroresponse
31. Jürchott K, Schulz AR, Bozzetti C, Pohlmann D, Stervbo U, Warth S, et al. Highly Predictive Model for a Protective Immune Response to the a(H1N1)Pdm2009 Influenza Strain After Seasonal Vaccination. *Kang S-M editor PloS One* (2016) 11(3):e0150812. doi: 10.1371/journal.pone.0150812
32. Romero-Olmedo AJ, Schulz AR, Huber M, Brehm CU, Chang H, Chiarolla CM, et al. Deep Phenotypical Characterization of Human CD3⁺ CD56⁺ T Cells by Mass Cytometry. *Eur J Immunol* (2021) 51(3):672–81. doi: 10.1002/eji.202048941
33. Van Acker HH, Capsomidis A, Smits EL, Van Tendeloo VF. CD56 in the Immune System: More Than a Marker for Cytotoxicity? *Front Immunol* (2017) 8:892. doi: 10.3389/fimmu.2017.00892
34. Godfrey DI, MacDonald HR, Kronenberg M, Smyth MJ, Kaer LV. NKT Cells: What’s in a Name? *Nat Rev Immunol* (2004) 4(3):231–7. doi: 10.1038/nri1309
35. Lang ML. The Influence of Invariant Natural Killer T Cells on Humoral Immunity to T-Dependent and -Independent Antigens. *Front Immunol* (2018) 9:305. doi: 10.3389/fimmu.2018.00305
36. Galli G, Pittoni P, Tonti E, Malzone C, Uematsu Y, Tortoli M, et al. Invariant NKT Cells Sustain Specific B Cell Responses and Memory. *Proc Natl Acad Sci* (2007) 104(10):3984–9. doi: 10.1073/pnas.0700191104
37. Dwivedi V, Manickam C, Dhalak S, Binjawadagi B, Ouyang K, Hiremath J, et al. Adjuvant Effects of Invariant NKT Cell Ligand Potentiates the Innate and Adaptive Immunity to an Inactivated H1N1 Swine Influenza Virus Vaccine in Pigs. *Vet Microbiol* (2016) 186:157–63. doi: 10.1016/j.vetmic.2016.02.028
38. Artiga BL, Yang G, Hackmann TJ, Liu Q, Richt JA, Salak-Ardakani S, et al. α-Galactosylceramide Protects Swine Against Influenza Infection When Administered as a Vaccine Adjuvant. *Sci Rep* (2016) 6(1):23593. doi: 10.1038/srep23593
39. Zingaropoli MA, Perri V, Pasculli P, Cogliati Dezza F, Nijhawan P, Savelloni G, et al. Major Reduction of NKT Cells in Patients With Severe COVID-19 Pneumonia. *Clin Immunol Orlando Fla* (2021) 222:108630. doi: 10.1016/j.clim.2020.108630
40. Slaunwhite D, Johnston B. Regulation of NKT Cell Localization in Homeostasis and Infection(2015) (Accessed 2021 May 23).
41. Rico MJ, Rozados VR, Mainetti LE, Zacarias Fluck MF, Matar P, Scharovsky OG. Regulatory T Cells But Not NKT I Cells Are Modulated by a Single Low-Dose Cyclophosphamide in a B Cell Lymphoma Tumor Model. *Exp Oncol* (2012) 5(1):38–42.
42. Larsson A-M, Roxå A, Leandersson K, Bergenfelz C. Impact of Systemic Therapy on Circulating Leukocyte Populations in Patients With Metastatic Breast Cancer. *Sci Rep* (2019) 9(1):13451. doi: 10.1038/s41598-019-49943-y

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.